Monday, December 15, 2025

Latest

Medipharm Labs Appoints Former Purdue Pharma Exec As CEO

Medipharm Labs (TSX: LABS) continues to suffer from management turnover. The company today announced that its CEO, Bryan Howcroft, will be stepping down for personal reasons effective immediately. Howcroft was in the role for just six months.

Taking Howcroft’s place within the company is that of David Piddick, whom Medipharm lists as previously serving as a president and CEO of a “Canadian pharmaceutical company.” That pharma company is believed to be Purdue Pharma Canada, whom notably faced numerous lawsuits related to the opioid pandemic which ultimately lead to a bankruptcy filing in the US. Piddick will also serve on the firms board of directors.

Piddick reportedly has over two decades worth of senior leadership experience within the healthcare industry. He currently holds a MBA from Northwestern University.

“In MediPharm, I see one of the very few organizations globally that has the required sophistication to both operate within a stringent Pharma environment, and scale rapidly to capitalize on this growth opportunity. I look forward to contributing my experience in business and corporate development to the team’s current efforts, with a focus on orienting the Company toward both consistent organic growth and accretive M&A activities to drive revenue growth, profitability and value for all stakeholders,” commented Piddick on his appointment.

As part of Piddick’s compensation package, he was issued 14.8 million RSU’s in connection with his appointment, as well as 5.2 million stock options.

Howcroft meanwhile has exited his role from the firm entirely, announcing this morning he will also be vacating his position on the firms board.

Medipharm Labs last traded at $0.145 on the TSX.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

2 Responses

Video Articles

Soma Gold: Q3 Earnings Impacted By Labour Strike

Thesis Gold: The Multi-Billion Dollar Lawyers-Ranch PFS

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Recommended

Steadright Locks Up Goundafa Polymetallic Mine Under Binding MOU

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project

Related News

MediPharm Labs Posts Revenues Of $5.5 Million, Net Loss Of $13.9 Million

MediPharm Labs (TSX: LABS) this morning continued its recent trend of dismal financing results, posting...

Monday, May 17, 2021, 07:54:52 AM

Medipharm Labs Signs White Label Arrangement With Shelter Brand House

Medipharm Labs (TSX: LABS) announced a white labeling agreement with that of 1193269 B.C. Ltd....

Thursday, January 9, 2020, 08:54:10 AM

MediPharm Labs Revenues Increase 37.8% to $43.38 Million

Medipharm Labs (TSX: LABS) announced third quarter earnings this morning, posting revenues of $43.38 million...

Tuesday, November 12, 2019, 08:44:55 AM

Medipharm Announces White Label Agreement With Argentia Gold

Medipharm Labs (TSX: LABS) and Argentia Gold Corp this morning jointly announced a supply agreement,...

Wednesday, May 27, 2020, 08:34:11 AM

Medipharm Labs: Canaccord Lowers Targets After Earnings

On August 16, Medipharm Labs (TSX: LABS) reported their second quarter financial results. The company...

Friday, August 20, 2021, 07:54:00 AM